查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1675350

非酒精性脂肪性肝炎市场（按药物类型、疾病原因、销售管道、最终用户和地区划分）2025 年至 2033 年

Non-Alcoholic Steatohepatitis Market by Drug Type, Disease Cause, Sales Channel, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 142 Pages | 商品交期: 2-3个工作天内

价格

2024 年全球非酒精性脂肪性肝炎 (NASH) 市场规模达到 19 亿美元。 展望未来， IMARC Group预计到 2033 年市场规模将达到 135 亿美元，2025-2033 年期间的成长率 (CAGR) 为 22.97%。 NASH 盛行率的上升、对早期诊断和治疗认识的提高以及人工智慧 (AI) 和机器学习 (ML) 技术的整合是推动市场发展的一些关键因素。

非酒精性脂肪性肝炎（NASH）是指由胰岛素抗性、过重和代谢症候群所引起的进行性非酒精性脂肪肝疾病（NAFLD）。其症状包括疲劳虚弱、体重减轻、黄疸、皮肤搔痒、蜘蛛静脉、肝臟肿大、注意力不集中、液体积聚、腹部不适，如疼痛和肿胀。此疾病透过多种技术进行诊断，例如身体检查、血液检查、肝臟活检、磁振造影 (MRI)、超音波和电脑断层扫描 (CT) 扫描。 NASH 治疗包括药物治疗、肝臟移植和各种生活方式的改变，如定期运动和健康饮食。这些治疗方法有助于减少肝臟脂肪堆积、改善肝功能、减少发炎并最大限度地减少肝损伤。它们还能提高患者的生活质量，改善长期疗效，并更好地管理肥胖和高血压等其他健康问题。

非酒精性脂肪性肝炎 (NASH) 市场趋势：

由于遗传、久坐的生活方式、不健康的饮食习惯、肥胖和 2 型糖尿病导致的 NASH 盛行率上升是推动市场成长的关键因素之一。与此相符的是，NASH 治疗被患者广泛采用，以缓解症状、延长寿命、防止过早死亡、改善肝臟健康和促进整体健康，这反过来又推动了市场成长。此外，人们越来越意识到早期诊断和治疗 NASH 可以减少医疗费用、消除肝臟移植的需要并预防高血压、心血管疾病 (CVD)、癌症、肝硬化和肝衰竭等未来併发症，这为市场成长提供了动力。此外，利用非侵入性影像技术监测和诊断 NASH，例如 MRI 和瞬时弹性成像 (TE)，进而提高患者的舒适度、提高依从性、降低併发症风险并改善临床结果，对市场成长产生正面影响。除此之外，人工智慧（AI）和机器学习（ML）的整合有利于开发个人化治疗、提高诊断准确性和预测疾病进展，进而促进市场成长。此外，政府实施各种倡议，提供高品质的治疗机会并支持先进治疗方法的发展，正在推动市场成长。其他因素，包括老年人口的增加、医疗保健支出的增加、广泛的研究和开发 (R&D) 活动、医疗保健行业的显着增长以及对非侵入性治疗方案的需求不断增加，预计将推动市场成长。

本报告解答的关键问题

  • 全球非酒精性脂肪性肝炎（NASH）市场有多大？ 2025 年至 2033 年期间全球非酒精性脂肪性肝炎 (NASH) 市场的预期成长率为何？
  • 推动全球非酒精性脂肪性肝炎 (NASH) 市场发展的关键因素有哪些？
  • COVID-19 对全球非酒精性脂肪性肝炎 (NASH) 市场有何影响？
  • 根据药物类型，全球非酒精性脂肪性肝炎 (NASH) 市场的分布如何？
  • 根据疾病原因，全球非酒精性脂肪性肝炎 (NASH) 市场如何分布？
  • 根据销售管道，全球非酒精性脂肪性肝炎 (NASH) 市场的分布如何？
  • 根据最终用户，全球非酒精性脂肪性肝炎 (NASH) 市场的分布如何？
  • 全球非酒精性脂肪性肝炎 (NASH) 市场的主要地区有哪些？
  • 全球非酒精性脂肪性肝炎 (NASH) 市场的关键参与者/公司是谁？

目录

第 1 章：前言

第 2 章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球非酒精性脂肪性肝炎 (NASH) 市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依药物类型

  • 维生素 E 和吡格列酮
  • 奥卡利瓦
  • 艾拉菲布兰诺
  • 塞隆塞替布
  • 西尼利韦罗
  • 其他的

第 7 章：市场区隔：依疾病原因

  • 高血压
  • 心臟病
  • 高血脂
  • 2 型糖尿病
  • 肥胖

第 8 章：市场区隔：依销售管道

  • 医院药房
  • 线上提供者
  • 零售药局

第 9 章：市场区隔：按最终用户

  • 医院
  • 诊所
  • 家庭护理设置

第 10 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第 11 章：驱动因素、限制因素与机会

  • 概述
  • 驱动程式
  • 限制
  • 机会

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第 15 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Algernon Pharmaceuticals
    • Galmed Pharmaceuticals Ltd
    • Intercept Pharmaceuticals Inc.
    • Zydus Lifesciences Limited
Product Code: SR112025A7397

The global non-alcoholic steatohepatitis (NASH) market size reached USD 1.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 13.5 Billion by 2033, exhibiting a growth rate (CAGR) of 22.97% during 2025-2033. The rising prevalence of NASH, increasing awareness regarding early diagnosis and treatments, and the integration of artificial intelligence (AI) and machine learning (ML) technologies represent some of the key factors driving the market.

Non-alcoholic steatohepatitis (NASH) refers to a progressive non-alcoholic fatty liver disease (NAFLD) caused by insulin resistance, overweight, and metabolic syndrome. Its symptoms involve fatigue and weakness, weight loss, jaundice, itchy skin, spider veins, enlarged liver, lack of concentration, fluid accumulation, and abdominal discomfort, such as pain and swelling. It is diagnosed through multiple techniques, such as physical examination, blood test, liver biopsy, magnetic resonance imaging (MRI), ultrasound, and computed tomography (CT) scan. NASH treatment includes medication, liver transplant, and various lifestyle modifications, such as regular exercise, and healthy diets. These treatment methods aid in reducing liver fat accumulation, improving liver function, reducing inflammation, and minimizing liver damage. They also enhance patients' quality of life, improve long-term outcomes, and allow better management of other health problems, such as obesity and high blood pressure.

Non-Alcoholic Steatohepatitis (NASH) Market Trends:

The rising prevalence of NASH due to genetics, sedentary lifestyle, unhealthy eating habits, obesity, and type 2 diabetes is one of the key factors driving the market growth. In line with this, NASH treatments are widely adopted by patients to alleviate symptoms, increase lifespan, prevent premature death, improve liver health, and promote overall well-being, which in turn is providing a thrust to the market growth. Furthermore, the increasing awareness among the masses regarding early diagnosis and treatment of NASH to reduce healthcare expenses, eliminate the need for liver transplants, and prevent future complications, such as high blood pressure, cardiovascular diseases (CVDs), cancer, cirrhosis, and liver failure is providing an impetus to the market growth. Additionally, the utilization of non-invasive imaging techniques to monitor and diagnose NASH, such as MRI and transient elastography (TE), which, in turn, enhances patients' comfort, increases compliance, reduces the risk of complications, and improves clinical outcomes, is positively influencing the market growth. Besides this, the integration of artificial intelligence (AI) and machine learning (ML) to develop personalized treatments, improve diagnosis accuracy, and predict disease progression is favoring the market growth. Moreover, the implementation of various government initiatives to provide access to high-quality treatment and support the development of advanced therapeutics is propelling the market growth. Other factors, including the rising geriatric population, increasing healthcare expenditure, extensive research and development (R&D) activities, significant growth in the healthcare industry, and the increasing demand for non-invasive treatment options, are anticipated to drive the market growth.

Key Market Segmentation:

Drug Type Insights:

  • Vitamin E and Pioglitazone
  • Ocaliva
  • Elafibranor
  • Selonsertib
  • Cenicriviroc
  • Others

Disease Cause Insights:

  • Hypertension
  • Heart Disease
  • High Blood Lipid
  • Type 2 Diabetes
  • Obesity

Sales Channel Insights:

  • Hospital Pharmacy
  • Online Providers
  • Retail Pharmacy

End User Insights:

  • Hospitals
  • Clinics
  • Homecare Settings

Regional Insights:

  • North America
  • United States
  • Canada
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for non-alcoholic steatohepatitis (NASH). Some of the factors driving the North America non-alcoholic steatohepatitis (NASH) market included the rising prevalence of NASH, increasing government initiatives, and rapid technological advancements.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global non-alcoholic steatohepatitis (NASH) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Algernon Pharmaceuticals, Galmed Pharmaceuticals Ltd, Intercept Pharmaceuticals Inc., Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1.How big is the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 2.What is the expected growth rate of the global Non-Alcoholic Steatohepatitis (NASH) market during 2025-2033?
  • 3.What are the key factors driving the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 4.What has been the impact of COVID-19 on the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 5.What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the drug type?
  • 6.What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the disease cause?
  • 7.What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the sales channel?
  • 8.What is the breakup of the global Non-Alcoholic Steatohepatitis (NASH) market based on the end user?
  • 9.What are the key regions in the global Non-Alcoholic Steatohepatitis (NASH) market?
  • 10.Who are the key players/companies in the global Non-Alcoholic Steatohepatitis (NASH) market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Non-Alcoholic Steatohepatitis (NASH) Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Vitamin E and Pioglitazone
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Ocaliva
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Elafibranor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Selonsertib
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Cenicriviroc
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Disease Cause

  • 7.1 Hypertension
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Heart Disease
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 High Blood Lipid
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Type 2 Diabetes
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Obesity
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Sales Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Online Providers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Retail Pharmacy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Clinics
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Homecare Settings
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

  • 11.1 Overview
  • 11.2 Drivers
  • 11.3 Restraints
  • 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Algernon Pharmaceuticals
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Galmed Pharmaceuticals Ltd
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
    • 15.3.3 Intercept Pharmaceuticals Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Zydus Lifesciences Limited
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Non-Alcoholic Steatohepatitis Market: Major Drivers and Challenges
  • Figure 2: Global: Non-Alcoholic Steatohepatitis Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Drug Type (in %), 2024
  • Figure 5: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Disease Cause (in %), 2024
  • Figure 6: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Sales Channel (in %), 2024
  • Figure 7: Global: Non-Alcoholic Steatohepatitis Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Non-Alcoholic Steatohepatitis Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Non-Alcoholic Steatohepatitis (Vitamin E and Pioglitazone) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Non-Alcoholic Steatohepatitis (Ocaliva) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Non-Alcoholic Steatohepatitis (Elafibranor) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Non-Alcoholic Steatohepatitis (Selonsertib) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Non-Alcoholic Steatohepatitis (Cenicriviroc) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Non-Alcoholic Steatohepatitis (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Non-Alcoholic Steatohepatitis (Hypertension) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Non-Alcoholic Steatohepatitis (Heart Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Non-Alcoholic Steatohepatitis (High Blood Lipid) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Non-Alcoholic Steatohepatitis (Type 2 Diabetes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Non-Alcoholic Steatohepatitis (Obesity) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Non-Alcoholic Steatohepatitis (Obesity) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Non-Alcoholic Steatohepatitis (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Non-Alcoholic Steatohepatitis (Online Providers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Non-Alcoholic Steatohepatitis (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Non-Alcoholic Steatohepatitis (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Non-Alcoholic Steatohepatitis (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Non-Alcoholic Steatohepatitis (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Non-Alcoholic Steatohepatitis (Homecare Settings) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: North America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: North America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: United States: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: United States: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Canada: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Canada: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Asia-Pacific: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Asia-Pacific: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: China: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: China: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Japan: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Japan: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: India: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: India: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: South Korea: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: South Korea: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Australia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Australia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Indonesia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Indonesia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Europe: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Europe: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Germany: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Germany: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: France: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: France: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: United Kingdom: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: United Kingdom: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Italy: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Italy: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Spain: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Spain: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Russia: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Russia: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Latin America: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Latin America: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Brazil: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Brazil: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Mexico: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Mexico: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Others: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Others: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Middle East and Africa: Non-Alcoholic Steatohepatitis Market: Breakup by Country (in %), 2024
  • Figure 91: Middle East and Africa: Non-Alcoholic Steatohepatitis Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 92: Global: Non-Alcoholic Steatohepatitis Industry: Drivers, Restraints, and Opportunities
  • Figure 93: Global: Non-Alcoholic Steatohepatitis Industry: Value Chain Analysis
  • Figure 94: Global: Non-Alcoholic Steatohepatitis Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Non-Alcoholic Steatohepatitis Market: Key Industry Highlights, 2024 & 2033
  • Table 2: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 3: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Disease Cause (in Million USD), 2025-2033
  • Table 4: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Sales Channel (in Million USD), 2025-2033
  • Table 5: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Non-Alcoholic Steatohepatitis Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Non-Alcoholic Steatohepatitis Market: Competitive Structure
  • Table 8: Global: Non-Alcoholic Steatohepatitis Market: Key Players